1. Search Result
Search Result
Pathways Recommended: MAPK/ERK Pathway
Results for "

MDA-MB-468 cells,Hedgehog pathway

" in MedChemExpress (MCE) Product Catalog:

3055

Inhibitors & Agonists

70

Screening Libraries

16

Fluorescent Dye

46

Biochemical Assay Reagents

153

Peptides

2

MCE Kits

50

Inhibitory Antibodies

931

Natural
Products

14

Recombinant Proteins

177

Isotope-Labeled Compounds

1

Antibodies

12

Click Chemistry

26

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-11038B
    Zelavespib hydrochloride
    1 Publications Verification

    PU-H71 hydrochloride

    HSP Cancer
    Zelavespib (PU-H71) hydrochloride is a potent Hsp90 inhibitor, with an IC50 of 51 nM in MDA-MB-468 cells.
    Zelavespib hydrochloride
  • HY-11038
    Zelavespib
    1 Publications Verification

    PU-H71

    HSP Cancer
    Zelavespib (PU-H71) is a potent Hsp90 inhibitor, with an IC50 of 51 nM in MDA-MB-468 cells.
    Zelavespib
  • HY-N8187

    Apoptosis Cancer
    Eupalinolide O is a sesquiterpene lactone with anticancer activities. Eupalinolide O induces cell apoptosis in human MDA-MB-468 breast cancer cells .
    Eupalinolide O
  • HY-159990

    Glutathione Peroxidase Cancer
    GPX4-IN-15 (Compound C1) is an inhibitor for GPX4, that inhibits 19.8% GPX4 at 1 μM. GPX4-IN-15 inhibits the proliferation of cancer cell MDA-MB-468, BT-549 and MDA-MB-231 with IC50 of 0.86, 0.96 and 0.48 μM .
    GPX4-IN-15
  • HY-11038D
    Zelavespib formic
    1 Publications Verification

    PU-H71 formic

    HSP Cancer
    Zelavespib formic (PU-H71 formic) is a potent Hsp90 inhibitor with an IC50 value of 51 nM for Hsp90 in MDA-MB-468 cells .
    Zelavespib formic
  • HY-101447

    EPH 116

    Src Apoptosis Cancer
    SI-2 (EPH 116) is an inhibitor for steroid receptor coactivator-3 (SRC-3), which reduces the transcriptional activity and protein concentration of SRC-3 in cells, exhibits cytotoxicity in cancer cell, inhibits migration of MDA-MB-468, induces apoptosis of MDA-MB-468. SI-2 inhibits the tumor growth in mouse models, without significant toxicity for heart and other major organs (20 mg/kg) .
    SI-2
  • HY-173002

    DNA Methyltransferase Cancer
    MS9024 is the degrader for DNA methyltransferase 1 that degrades DNMT1 in cell HCT116 through the ubiquitin-proteasome pathway with a DC50 of 35 nM (DC50 in MDA-MB-468 and H1299 is 254 nM and 101 nM). MS9024 also inhibits DNMT1 with an IC50 of 0.43 μM .
    MS9024
  • HY-145860

    Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    PHGDH-IN-2 is a potent and NAD + competitive PHGDH inhibitor with an IC50 of 5.2 µM. PHGDH-IN-2 inhibits the serine synthetic pathway in MDA-MB-468 cells. PHGDH-IN-2 inhibits the growth of PHGDH-dependent cancer cells .
    PHGDH-IN-2
  • HY-158170

    CDK Cancer
    CDK7-IN-28 (CDK7-1276) is a potent CDK7 inhibitor(IC50<5 nM). CDK7-IN-28 can inhibit proliferation of MDA-MB-468 cell line by blocking cell cycle and inhibiting DNA replication .
    CDK7-IN-28
  • HY-155787

    CDK Cancer
    SHR5428 is a potent, orally active, selective and noncovalent inhibitor of CDK7 with highly potent CDK7 enzymatic activity (IC50=2.3 nM). SHR5428 inhibits triple negative breast cancer cellular activity on MDA-MB-468 cell (IC50=6.6 nM) .
    SHR5428
  • HY-159576

    O-Me B1939; O-Me E7389; O-Me ER-086526

    ADC Cytotoxin Cancer
    O-Me Eribulin is a derivative of Eribulin and is an ADC cytotoxin that can be used for ADC synthesis. O-Me Eribulin can inhibit the cell viability of SKBR3, MDA-MB-468, and A549 cells, with IC50 values of 0.2052, 0.1827, and 0.5151 nM, respectively. O-Me Eribulin can be used for tumor research .
    O-Me Eribulin
  • HY-143293

    VEGFR Apoptosis Cancer
    VEGFR-IN-3 (compound 3f) is a VEGFR inhibitor. VEGFR-IN-3 inhibits OVCAR-4 and MDA-MB-468 cancer cells growth with IC50s of 0.29 and 0.35 μM, respectively. VEGFR-IN-3 can be used for the research of cancer .
    VEGFR-IN-3
  • HY-147670

    Hedgehog Smo Gli Apoptosis Cancer
    TPB15 is an orally active and potent Hh (Hedgehog) signaling inhibitor. TPB15 markedly induces cell cycle arrest and apoptosis in MDA-MB-468 cells. TPB15 blocks Smo (Smoothened) translocation into the cilia and reduced Smo protein and mRNA expression. TPB15 inhibits the expression of the downstream regulatory factor glioma-associated oncogene 1 (Gli1). TPB15 shows good anti-tumor activity with low toxicity .
    TPB15
  • HY-P10760

    Peptide-Drug Conjugates (PDCs) Cancer
    PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC50 values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells .
    PhAc-ALGP-Dox
  • HY-151630

    Carbonic Anhydrase Cancer
    hCAIX-IN-16 (Compound 12d) is hCA IX inhibitor, with Ki values of 190.0 and 187.9 nM for hCA IX and hCA XII, respectively. hCAIX-IN-16 can arrest the cell cycle of breast cancer MDA-MB-468 in G0-G1 and S phase and induce apoptosis. hCAIX-IN-16 shows good broad-spectrum anticancer activity and can be used for cancer research .
    hCAIX-IN-16
  • HY-168037

    PROTACs PIN1 Cancer
    PROTAC PIN1 degrader-1 (compound D4) is a PROTAC targeting PIN1, with a DC50=1.8 nM. The GI50 of PROTAC PIN1 degrader-1 to MDA-MB-468 is >30 μM. PROTAC PIN1 degrader-1 is composed of target protein ligand PIN1 ligand-1 (HY-168038) (red part), E3 ligase ligand Thalidomide (HY-14658) (blue part), and PROTAC linker (black part) [1] .
    PROTAC PIN1 degrader-1
  • HY-160899A

    Drug-Linker Conjugates for ADC Cancer
    Thailanstatin A cyclohexane diamine formic is an analog of Spliceostatin (HY-16466). Thailanstatin A cyclohexane diamine formic inhibits proliferations of cells N87 (IC50 is 0.33 μM), BT474 (IC50 is 0.34 μM), MDA-MB-361-DYT2 (IC50 is 0.88 μM) and MDA-MB-468 (IC50 is 0.27 μM). Thailanstatin A cyclohexane diamine formic is used as a drug-linker conjugate for ADC molecule .
    Thailanstatin A cyclohexane diamine formic
  • HY-155113

    PROTACs HSP Cancer
    PROTAC Hsp90α degrader 1 (Compound X10g) is a selective PROTAC Hsp90α degrader. PROTAC Hsp90α degrader 1 can be used for breast cancer research. PROTAC Hsp90α degrader 1 inhibits the proliferation of MDA-MB-231, MDA-MB-468, MCF-7, MX-1 cells with IC50s of 51.48 μM, 16.46 μM, 8.93 μM, 11.95 μM respectively .
    PROTAC Hsp90α degrader 1
  • HY-146452

    Apoptosis Cancer
    Anticancer agent 57 (compound 14) potently inhibits MDA-MB-231, MDA-MB-468, and MCF-7 cell lines, with IC50s of 6.43 ~ 8.00 μM. Anticancer agent 57 induces cell cycle arrest and significantly promotes apoptosis. Anticancer agent 57 inhibits tumor growth in nude mice xenografted with MADMB-231 cells. Anticancer agent 57 can be used for researching triple negative breast cancer (TNBC) .
    Anticancer agent 57
  • HY-162751

    HSP Apoptosis Cancer
    Anticancer agent 249 (Compound 89) is an inhibitor for Hsp90β with IC50 of 16.5 μM in PC3MM2 cell. Anticancer agent 249 inhibits proliferation of cancer cells MCF-7, T47D, MDA-MB-231, MDA-MB-468 and SKBr3 with IC50 of 1.8-5.3 μM. Anticancer agent 249 induces apoptosis in MDA-MB-231. Anticancer agent 249 exhibits antitumor efficacy in mice .
    Anticancer agent 249
  • HY-161456

    Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    PHGDH-IN-5 (Compound B12) is a covalen inhibitor of PHGDH with an IC50 value of 0.29 μM. PHGDH-IN-5 can inhibit cell proliferation in cancer cell lines overexpressing PHGDH. PHGDH-IN-5 can reduce the production of serine derived from glucose in MDA-MB-468 cells .
    PHGDH-IN-5
  • HY-152945

    NF-κB Cancer
    Antiproliferative agent-22 (compound 2) is an anticancer agent. Antiproliferative agent-22 shoes anti-proliferative activities against MCF-7, MDA-MB-231 and MDA-MB-468 cells with IC50 values of 6.2 μM, 3.3 μM and 3.3 μM, respectively .
    Antiproliferative agent-22
  • HY-155098

    SHP2 Cancer
    CNBCA is a potent, selective, competitive SHP2 enzyme inhibitor, with the IC50 of 0.87 μM. CNBCA binds to full-length SHP2 and inhibits enzyme activity. CNBCA inhibits pAkt and pERK1/2, and the cell growth of BT474 and MDA-MB468 cells. CNBCA can be used for breast cancer study .
    CNBCA
  • HY-170947

    STAT Quinone Reductase Cancer
    Antitumor agent-195 (compound 16c) is a dual targeting agent of STAT3 and NQO1. Antitumor agent-195 significantly inhibits phosphorylation of STAT3 at Tyr705 at a concentration of 1 μM and effectively induce Apoptosis in MDAMB-231 and MDA-MB-468 breast cancer cells. Antitumor agent-195 as a NQO1 substrate strongly increases ROS generation and causes severe DNA damage in a dose-dependent manner. Antitumor agent-195 shows encouraging anti-tumor efficacy in the MDA-MB-231 xenograft model .
    Antitumor agent-195
  • HY-160598

    ADC Cytotoxin Topoisomerase Cancer
    Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol (compound 45) is a camptothecin compound that can inhibit cell proliferation, with an IC50 of 2.92 ng/mL for MDA‑MB‑468 cells. Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol can be used for the research of cancer .
    Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol
  • HY-173060

    ERK Apoptosis Autophagy Cancer
    ERK1/2 inhibitor 13 (Compound 21y) is the orally active inhibitor for ERK that inhibits ERK1 and ERK2 with IC50 of 91.71 nM and 97.87 nM. ERK1/2 inhibitor 13 inhibits the proliferation of MCF-7, 4T1, MDA-MB-468, and HCC1970 (IC50 of 0.67, 2.76, 2.15 and 1.68 μM), inhibits the cancer cell migration, induces apoptosis and autophagy in MCF-7. ERK1/2 inhibitor 13 exhibits antitumor and anti-metastatic effect in 4T1 xenograft mouse model .
    ERK1/2 inhibitor 13
  • HY-163709

    PROTACs FAK Cancer
    PROTAC FAK degrader 2 (Compound F2) is a PROTAC degrader for focal adhesion kinase (FAK), with DC50 of 27.72 and 60.1 nM, for total FAK and phosphorylated p-FAK. PROTAC FAK degrader 2 inhibits cell viability of cancer cells 4T1, MDA-MB-231, MDA-MB-468 and MDA-MB-435, with IC50s of 0.73-5.84 μM. PROTAC FAK degrader 2 reverses the multidrug resistance (MDR) through inhibition of AKT and ERK signaling pathway. PROTAC FAK degrader 2 exhibits antitumor efficacy in HCT/8 xenograft mouse model. (Pink: ligand for target protein Ifebemtinib (HY-122844); Black: linker (HY-Y0681); Blue: ligand for E3 ligase Thalidomide (HY-14658))
    PROTAC FAK degrader 2
  • HY-150613

    Epigenetic Reader Domain PARP Apoptosis Cancer
    PARP1/BRD4-IN-2 is a potent and selective PARP1 and BRD4 inhibitor with IC50 values of 197 nM and 238 nM, respectively. PARP1/BRD4-IN-2 inhibits DNA damage repair, arrests G0/G1 transition and induces apoptosis. PARP1/BRD4-IN-2 has anti-tumor activity in MDA-MB-468 xenograft mouse model. PARP1/BRD4-IN-2 can be used for researching triple-negative breast cancer (TNBC) .
    PARP1/BRD4-IN-2
  • HY-155180

    PI3K Cancer
    FD2056 is a potent and orally active PI3K inhibitor. FD2056 inhibits PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ with IC50s of 0.30, 0.80, 1.10, 0.42 nM. FD2056 also inhibits CDK2-CyclinA2 and CDK4-CyclinD3 with IC50 of 115.95 and 2782.15 nM. FD2056 inhibits breast cancer cell proliferation with IC50s of 1.06, 0.04, 1.40 μM for MDA-MB-231, MDA-MB-468, MCF-7 cells. FD2056 also induces cancer apoptosis and inhibits tumor growth .
    FD2056
  • HY-129426

    Akt Cancer
    PDK1/Akt/Flt dual pathway inhibitor is one of a component of KP372-1 (HY-15673 ), and inhibits PDK1/Akt/Flt dual pathway .
    PDK1/Akt/Flt dual pathway inhibitor
  • HY-112338

    CPD188

    STAT Apoptosis Cancer
    C188 (CPD188) is a STAT3 inhibitor with anticancer effects. C188 inhibits STAT3 SH2/pY-peptide binding (IC50 of 20 µM against pY-peptide binding) and IL-6-mediated STAT3 phosphorylation. C188 is selective for STAT3 over STAT1. C188 inhibits nuclear-to-cytoplasmic translocation of Stat3. C188 shows highly active induces apoptosis in breast cancer cell lines with constitutive Stat3 activation (EC50s of 0.73 µM, 3.96 µM, and 7.01 µM in MDA-MB-468, MDA-MB-231, and MDA-MB-435 cultures, respectively) .
    C188
  • HY-169730

    Wnt Cancer
    Wnt pathway inhibitor 5 (Compound 28) is wnt pathway inhibitor, with an IC50 value of < 0.003 μΜ. Wnt pathway inhibitor 5 inhibits many cancers, including ovarian teratocarcinoma cancer, breast cancer, osteosarcoma, head and neck squamous carcinoma .
    Wnt pathway inhibitor 5
  • HY-153750

    Wnt Cancer
    Wnt pathway inhibitor 3 is a potent wnt inhibitor with an IC50 value of 45 nM. Wnt pathway inhibitor 3 shows antiproliferative activity .
    Wnt pathway inhibitor 3
  • HY-136073

    Wnt Cancer
    Wnt pathway activator 2 (compound 2) is a potent Wnt activator with an EC50 of 13 nM .
    Wnt pathway activator 2
  • HY-153753

    Wnt Cancer
    Wnt pathway inhibitor 4 (compound 16D) is an anticancer agent that has anti-proliferative activity .
    Wnt pathway inhibitor 4
  • HY-136541
    YB-0158
    2 Publications Verification

    Wnt pathway inhibitor 2

    Wnt Apoptosis Cancer
    YB-0158 (Wnt pathway inhibitor 2) is a reverse-turn peptidomimetic and a potent colorectal cancer stem cell (CSC) targeting agent. YB-0158 disrupts Sam68-Src interactions and induces apoptosis in CRC cells. Anti-cancer activities .
    YB-0158
  • HY-B1899A
    Taurodeoxycholic acid sodium hydrate
    5 Publications Verification

    Sodium taurodeoxycholate monohydrate

    G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Metabolic Disease
    Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Taurodeoxycholic acid sodium hydrate activates the S1PR2 pathway in addition to the TGR5 pathway .
    Taurodeoxycholic acid sodium hydrate
  • HY-W089835R

    G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Metabolic Disease
    Sodium taurodeoxycholate hydrate (Standard) is the analytical standard of Sodium taurodeoxycholate hydrate. This product is intended for research and analytical applications. Sodium taurodeoxycholate hydrate, a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Sodium taurodeoxycholate hydrate activates the S1PR2 pathway in addition to the TGR5 pathway .
    Sodium taurodeoxycholate hydrate (Standard)
  • HY-P99965

    SKY59; RO7112689

    Complement System Cardiovascular Disease Metabolic Disease
    Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
    Crovalimab
  • HY-Y0641
    3-Phenoxybenzaldehyde
    1 Publications Verification

    m-Phenoxybenzaldehyde

    Complement System Inflammation/Immunology
    3-Phenoxybenzaldehyde has weak complement classical pathway inhibition and hemolytic activity .
    3-Phenoxybenzaldehyde
  • HY-N9474

    5-Diphosphomevalonic acid tetralithium; Mevalonic acid 5-diphosphate tetralithium

    Endogenous Metabolite Others
    Mevalonic acid 5-pyrophosphate (5-Diphosphomevalonic acid) tetralithium is an endogenous metabolite of the mevalonate pathway .
    Mevalonic acid 5-pyrophosphate tetralithium
  • HY-12848C
    SAG dihydrochloride
    25+ Cited Publications

    Smo Cancer
    SAG dihydrochloride is a potent Smoothened (Smo) receptor agonist (EC50=3 nM; Kd=59 nM). SAG dihydrochloride activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .
    SAG dihydrochloride
  • HY-79256
    MMAF-OMe
    1 Publications Verification

    Monomethyl auristatin F methyl ester

    ADC Cytotoxin Cancer
    MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC50s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4 -) cell lines, respectively.
    MMAF-OMe
  • HY-N1930

    Hinesol

    Apoptosis Cancer
    (-)-Hinesol (Hinesol) is a potent anticancer agent. (-)-Hinesol induces apoptosis and cell cycle arrest at G0/G1 phase. (-)-Hinesol downregulates MEK/ERK pathway and NF-κB pathway and mediates theexpression of cyclin D1, Bax and Bcl-2. (-)-Hinesol has the potential for the research of non–small cell lung cancer .
    (-)-Hinesol
  • HY-W777433

    Endogenous Metabolite Infection Others
    Cyclobenzaprine b-D-glucuronide is a metabolite of Cyclobenzaprine. Cyclobenzaprine b-D-glucuronide can be used to treat diseases associated with coronavirus infection. Cyclobenzaprine b-D-glucuronide can be used to study the metabolic pathways of Cyclobenzaprine in the body and as a potential candidate for studying coronavirus treatment .
    Cyclobenzaprine b-D-glucuronide
  • HY-155646

    NF-κB Inflammation/Immunology
    Anti-inflammatory agent 48 is an anti-inflammatory agent based on its role in inhibiting the NF-κB signaling pathway and activating HO-1 expression .
    Anti-inflammatory agent 48
  • HY-153456

    Hedgehog Cancer
    Hedgehog IN-2 (Compound 20) is an inhibitor of Hedgehog pathway with an IC50 value less than 0.003 μM in C3H10T1/2 cells .
    Hedgehog IN-2
  • HY-168951

    Annexin A Apoptosis Cancer
    (R)-SL18 is a degrader of ANXA3 and can degrade ANXA3 protein through the ubiquitination pathway. (R)-SL18 inhibits the proliferation, migration, invasion, and colony formation of breast cancer cells and induces apoptosis. (R)-SL18 can be used in the research of triple-negative breast cancer .
    (R)-SL18
  • HY-147789

    Akt Neurological Disease Cancer
    FPDT is an anti-glioblastoma agent. FPDT displays the IC50 value of 45–68 μM for GBM cells and >100 μM for astrocytes. Anti-glioblastoma activity of FPDT is linked to downregulation of the AKT pathway .
    FPDT
  • HY-15398C

    Epicholecalciferol

    Hedgehog Cancer
    3-epi-Vitamin D3 (Epicholecalciferol) (Compound 4), a Vitamin D3 analogue, is a Hedgehog pathway inhibitor with an IC50 of 39.2 μM measured in U87MG cells .
    3-epi-Vitamin D3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: